Establishment Labs Holdings Inc. (ESTA) shares soared 6.70% in the after-hours trading session on Wednesday, following the company's fourth quarter and full-year 2024 earnings release. The rally was driven by Establishment Labs' upbeat 2025 guidance and the successful launch of its Motiva breast implants in the U.S. market.

The medical device company reaffirmed its 2025 revenue guidance of $205 million to $210 million, representing a 23% to 26% increase over 2024. This growth is expected to be fueled by strong demand for Motiva implants in the U.S., where the company reported $3.3 million in sales during the fourth quarter. Establishment Labs expects U.S. Motiva sales to reach $35 million in 2025, as the product gains traction among plastic surgeons and patients.

Additionally, the company is effectively managing its expenses and aims to turn cash flow positive in 2025, driven by the ramp-up of its U.S. business. Establishment Labs also launched its new Preservé minimally invasive breast surgery technology in Brazil during the quarter, expanding its product portfolio.